Brian Pflugh, PA
Medical · Pittsburgh, PANPI 1063708931
Payments from drug & device makers
Across 101 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$353
- Novo Nordisk$266
- Amgen$253
- E.r. Squibb & Sons, L.L.C.$228
- Impulse Dynamics (USA) Inc.$209
- Boehringer Ingelheim$169
- plus $714 from 12 others
Across 3 payments — averaging $116.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$350
What the payments were for
- Food & beverage$2,193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $353 |
| Novo Nordisk | 13 | $266 |
| Amgen | 13 | $253 |
| E.r. Squibb & Sons, L.L.C. | 12 | $228 |
| Impulse Dynamics (USA) Inc. | 6 | $209 |
| Boehringer Ingelheim | 7 | $169 |
| Pfizer | 8 | $157 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $126 |
| Heartflow, Inc. | 4 | $105 |
| Johnson & Johnson | 4 | $89 |
| Teleflex LLC | 3 | $85 |
| Abiomed | 1 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
How this compares
$2,193 in reported general payments places this provider in the 80th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 247 | $175,738 |
| EntrestoSacubitril/Valsartan | 73 | $70,435 |
| BrilintaTicagrelor | 69 | $40,470 |
| JardianceEmpagliflozin | 44 | $38,127 |
| Repatha SureclickEvolocumab | 60 | $33,580 |
| Ranolazine ErRanolazine | 103 | $7,299 |
| Metoprolol Succinate | 346 | $2,944 |
| Potassium Chloride | 72 | $2,164 |
| Atorvastatin Calcium | 234 | $2,083 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 200 | $1,891 |
| Bumetanide | 56 | $1,300 |
| Ezetimibe | 97 | $1,269 |
| Rosuvastatin Calcium | 121 | $1,248 |
| ClopidogrelClopidogrel Bisulfate | 216 | $1,101 |
| Pantoprazole Sodium | 202 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $175,738247 claims |
| NovartisEntresto | $353 | $70,43573 claims |
| AstraZenecaBrilinta | $14 | $40,47069 claims |
| Boehringer IngelheimJardiance | $169 | $38,12744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Pittsburgh
- Patrick OffiPittsburgh$63K
- Haley WhitePittsburgh$34K
- Allyson Zella PraterPittsburgh$32K
- Braeden BashPittsburgh$27K
- Caroline O'NeilPittsburgh$25K
- Michael TometskoPittsburgh$16K
- Tori PipakPittsburgh$15K
- Juliette Bender HeinePittsburgh$15K
- Aimee HerringtonPittsburgh$14K
- Sarah AbrahamPittsburgh$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.